Table 2.
Stratified Vaccine Effectiveness and 95% Confidence Intervals for RV5 and RV1, Using the Rotavirus-Negative Acute Gastroenteritis Control Group
| Stratum | RV5 |
RV1 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cases/Controls | VE (95% CI)a | Cases/Controls | VE (95% CI)a | |||||||
| Dose No. | ||||||||||
| Dose 1 | 233/537 | 70% (50%–82%) | 46/83 | 57% (−45% to 87%) | ||||||
| Dose 2 | 239/638 | 78% (65%–86%) | 56/140 | 70% (39% to 86%) | ||||||
| Dose 3 | 307/1445 | 84% (78%–88%) | NA | NA | ||||||
| Season | ||||||||||
| 2010 (% fully vaccinated) | 111/924 (23%/53%) | 82% (69%–89%) | 7/59 (0%/46%) | Φ | ||||||
| 2011 (% fully vaccinated) | 248/887 (29%/62%) | 84% (77%–89%) | 53/96 (26%/47%) | 64% (23%–83%) | ||||||
| Clinical setting | ||||||||||
| Inpatient | 130/372 | 86% (74%–91%) | 22/34 | 32% (−156% to 82%) | ||||||
| ED | 229/1439 | 81% (70%–84%) | 38/121 | 78% (46%–91%) | ||||||
| Age | ||||||||||
| 1 y | 34/402 | 85% (63%–94%) | 7/54 | 56% (−59% to 100%) | ||||||
| 2 y | 121/681 | 89% (82%–93%) | 46/79 | 86% (60%–95%) | ||||||
| 3 y | 91/414 | 83% (69%–90%) | 7/22 | Φ | ||||||
| 4 y | 86/231 | 79% (56%–90%) | 0/0 | Φ | ||||||
| Predominant genotype | ||||||||||
| G1P[8] | 15/NA | 89% (41%–98%) | 1/NA | Φ | ||||||
| G2P[4] | 82/NA | 87% (77%–93%) | 7/NA | Φ | ||||||
| G3P[8] | 196/NA | 87% (81%–91%) | 44/NA | 74% (40%–89%) | ||||||
| G12P[8] | 36/NA | 83% (57%–93%) | 4/NA | Φ | ||||||
| Ethnicity | ||||||||||
| Hispanic | 160/908 | 85% (76%–90%) | 12/30 | 59% (−100% to 91%) | ||||||
| Non-Hispanic | 199/902 | 83% (75%–88%) | 48/125 | 76% (44%–90%) | ||||||
Abbreviations: CI, confidence interval; ED, emergency department; NA, not applicable; RV1, Rotarix; RV5, RotaTeq; VE, vaccine effectiveness.
a
Exact odds ratio and 95% CI.
Φ = Insufficient RV1 coverage/subjects (see text).